U.S. stock index futures slipped on Thursday as a rally fueled by the U.S.-China tariff truce appeared to ease, while UnitedHealth fell after a report of a DoJ investigation into the health insurer.

UnitedHealth Group shares rebounded modestly Wednesday following yesterday's crash, with analysts from UBS, Oppenheimer, and Morgan Stanley leaving their ratings unchanged after the health insurer pulled its outlook and announced its CEO had stepped down.

UnitedHealth Group's stock has plunged nearly 50% due to the CEO resignation, withdrawal of guidance, and ongoing legal issues, creating a potential buying opportunity. The stock is deeply oversold with an RSI of 15, trading below both the 200-day and 50-day moving averages, indicating capitulation.

UnitedHealth is being investigated by the Justice Department for possible criminal Medicare fraud, The Wall Street Journal reports, while Dick’s Sporting Goods is close to buying Foot Locker for $2.3 billion.

Even UnitedHealth will struggle to overcome parasitic medical costs that Warren Buffett once called a tapeworm eating away at U.S. economic competitiveness. The $300 billion healthcare conglomerate reinstalled Chairman Stephen Hemsley as CEO and yanked its financial guidance.

An analyst reluctantly downgraded UnitedHealth’s stock, as the price plunge and a suspended full-year outlook was just too much to hold a bullish stance.

UnitedHealth Group Incorporated's stock faces a steep decline amid leadership turmoil, regulatory pressures, and rising costs. Click to read why UNH is a Hold.

John Ransom, Raymond James director of healthcare research, joins 'Power Lunch' to discuss why Ransom has pause on shares of UnitedHealth, why the company withdrew its guidance, and much more.